Biotech, Financing, Insight journal - Dealtalk

Biotech IPO: Stemline makes first IPO debut of 2013

Posted on 31 January 2013

Tags: , , ,

Biotech IPO: Stemline Therapeutics, an emerging biotech company, successfully completed its biotech IPO yesterday with shares rising 18% on opening.

Stemline increased the number of shares in the initial public offering, or IPO, by about one million, bringing the offering's value to $33 million, or $6 million more than the top estimate previously outlined in documents filed with the Securities and Exchange Commission.

Stemline Therapeutics, an emerging biotech company, is a clinical stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) as well as the tumor bulk. Among Stemline's drug candidates are SL-401 and SL-701, both of which have demonstrated single agent clinical activity in Phase 1/2 studies of advanced cancer patients.

Full details of the this biotech IPO, together with all S1 filings can be found at Current Agreements.

Steve Poile


Related items:

View: Financing Scorecard - the top deals by value

Read: Latest pharma and biotech financings

Signup: Current Partnering Dealmakers News - weekly email newsletter reviewing the previous weeks deal trends

Signup: Current Agreements Deals Review - monthly review of previous months deals, M&A and financings

Subscribe: Current Agreements - life science licensing, partnering, deals, M&A and financings database

Print Friendly, PDF & Email

Leave a Reply